# A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms

> **NCT04339400** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Myeloproliferative Neoplasms

## Interventions

- **DRUG:** TQ05105

## Key facts

- **NCT ID:** NCT04339400
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-20
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04339400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04339400, "A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04339400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*